论文部分内容阅读
目的:观察血脂康对新发2型糖尿病(T2DM)合并超重患者胰岛素抵抗的影响。方法:选取60例初诊T2DM合并肥胖患者随机分为两组。对照组予二甲双胍0.5 g/次,3次/d治疗,观察组在对照组治疗基础上加用血脂康胶囊0.6 g/次,2次/d,连续治疗3个月,检测治疗前后患者空腹血糖(FBG),空腹胰岛素(FINS),糖化血红蛋白(Hb A1c),细胞介素-1(IL-1),白细胞介素-6(IL-6),肿瘤坏死因子-α(TNF-α)水平,计算体重指数(BMI)及胰岛素抵抗指数(HMOA-IR);以Hb A1c<6.5%为血糖控制达标标准,分别计算两组治疗后血糖达标率。结果:治疗3个月后,两组BMI,FBG,FINS,HOMA-IR,Hb A1c,IL-1,IL-6,TNF-α均较治疗前下降(P<0.05),观察组FBG,FINS,HOMA-IR,IL-1,IL-6,TNF-α水平低于对照组(P<0.05),Hb A1c,BMI水平较对照组无明显变化;观察组FBG,FINS,Hb A1c,HOMA-IR,IL-1,IL-6,TNF-α治疗前后的差值大于对照组(P<0.05),BMI的差值两组相比无明显变化;观察组血糖达标率为80.0%(24/30),高于对照组的血糖达标率为66.7%(20/30),但二者差别无统计学意义。结论:血脂康胶囊能够改善新发T2DM合并超重患者的胰岛素抵抗程度,减轻体内炎症反应。
Objective: To observe the effect of Xuezhikang on insulin resistance in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and overweight. Methods: Sixty cases of newly diagnosed T2DM with obesity were randomly divided into two groups. The control group was treated with metformin 0.5 g / time, 3 times / d. The observation group was treated with 0.6% Xuezhikang capsule twice daily for 3 months. The fasting blood glucose (FBG), fasting insulin (FINS), Hb A1c, IL-1, IL-6 and TNF- , Body mass index (BMI) and insulin resistance index (HMOA-IR) were calculated. Hb A1c <6.5% was the standard of glycemic control, and the blood glucose compliance rate was calculated after treatment. Results: After 3 months treatment, the levels of BMI, FBG, FINS, HOMA-IR, Hb A1c, IL-1, IL-6 and TNF- , HOMA-IR, IL-1, IL-6 and TNF-α in the observation group were lower than those in the control group (P <0.05) The difference between before and after treatment of IR, IL-1, IL-6 and TNF-α was higher than that of the control group (P <0.05), but there was no significant difference between the two groups in the difference of BMI; 30). The blood glucose compliance rate was 66.7% (20/30) higher than the control group, but the difference was not statistically significant. Conclusion: Xuezhikang capsule can improve the degree of insulin resistance in newly diagnosed T2DM patients with overweight and relieve inflammation in vivo.